Core Viewpoint - Labcorp Holdings (LH) is expected to report quarterly earnings of $4.14 per share, reflecting a 5.1% increase year-over-year, with revenues projected at $3.49 billion, an 8.3% increase from the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised down by 0.1% in the last 30 days, indicating a reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenues- Biopharma Laboratory Services' at $743.20 million, a 5.1% increase from the prior-year quarter [5]. - The average estimate for 'Revenues- Diagnostics Laboratories' is $2.74 billion, reflecting an 8.7% increase year-over-year [5]. Operating Income Estimates - 'Adjusted Operating Income- Biopharma Laboratory Services' is projected to reach $117.62 million, up from $107.40 million in the same quarter last year [6]. - 'Adjusted Operating Income- Diagnostics Laboratories' is expected to be $466.41 million, compared to $441.50 million a year ago [6]. Stock Performance - Labcorp shares have returned -6.9% over the past month, contrasting with the Zacks S&P 500 composite's +5.4% change [6]. - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [6].